Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria

Allergy. 2019 Jun;74(6):1185-1187. doi: 10.1111/all.13714. Epub 2019 Jan 25.

Authors

L S Spekhorst¹, J M P A van den Reek², A C Knulst¹, H Röckmann¹

Affiliations

¹ Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.
² Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.

PMID: 30593687
DOI: 10.1111/all.13714

No abstract available

Publication types

Letter

MeSH terms

Adult
Anti-Allergic Agents / administration & dosage
Anti-Allergic Agents / adverse effects*
Anti-Allergic Agents / therapeutic use*
Chronic Urticaria / drug therapy*
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Omalizumab / administration & dosage
Omalizumab / adverse effects*
Omalizumab / therapeutic use*
Prospective Studies
Treatment Outcome

Substances

Anti-Allergic Agents
Omalizumab